News
ESMO: Immunotherapy combos extend lives in bladder cancer
In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has …
19791 items found
Sales & Marketing
Enhancing pharma brand performance through in-depth customer engagement insights
In today’s dynamic pharmaceutical landscape, having a high level of …
News
ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC
Roche’s Alecensa has become the first drug in the ALK inhibitor class …
News
ESMO: Opdivo chases Keytruda in perioperative lung cancer
Just days after MSD claimed an FDA approval for Keytruda as a pre- …
News
Amwell, Leidos win $180m US military digital health contract
Faced with escalating costs, the US Defense Health Agency (DHA) is …
Oncology
News
Young hit hardest by England’s ‘community health crisis’
New data from NHS England has revealed that the waiting list for …
News
EU clears path for Pfizer’s takeover of Seagen
Pfizer’s $43 billion acquisition of antibody-drug conjugate …
News
MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo
Daiichi Sankyo’s antibody-drug conjugate (ADC) franchise has …
Oncology
How quality of life can drive equitable cancer care and outcomes
Health inequalities are increasingly evident and affect more people …
News
Beam cuts one in five staffers to conserve cash
Gene-editing company Beam Therapeutics has shifted into reverse, …
R&D
One Health: The interconnection of animal and human health
There’s a tendency to overlook the fact that human health and animal …
News
NICE backs first ophthalmic bevacizumab for NHS use
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related m
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Sales & Marketing
Sponsored
Seeking a single source of truth: Standardisation of the dat...
Oskar Mӧbert, Vice President of OpenData at Veeva Systems, spoke with Ian Cornish, Associate Director of Data Platforms at Astellas, about the company’s decision to opt into Veeva’s OpenDat
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
Europe’s Largest Industry-Led & Dedicated Gathering for mRNA...
The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets,
R&D
Partner Content
Proteomic Based Drug Discovery Summit 2025
Determine Optimum Application of Proteomics to Accelerate Screening of Novel Targets, Unravel the Mode of Action, & Identify Biomarkers to Progress Small Molecule Drug Discovery & T
